Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

References

• Hyuna Sung JFM, Siegel RL, Laversanne M, Isabelle Soerjomataram MD, Ahmedin Jemal DMV, Bray BSc F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(209–249):209. doi:10.3322/caac.21660
   PubMedGoogle Scholar
• Yin L, Lu S, Zhu J, Zhang W, Ke G. Ovarian transposition before radiotherapy in cervical cancer patients: functional outcome and the adequate dose constraint. Radiat Oncol. 2019;14(1):100. doi:10.1186/s13014-019-1312-2
   PubMedGoogle Scholar
• Monk BJ, Enomoto T, Kast WM, et al. Integration of Immunotherapy into Treatment of Cervical Cancer: recent Data and Ongoing Trials. Cancer Treat Rev. 2022;106:102385. doi:10.1016/j.ctrv.2022.102385
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33(19):2129–2135. doi:10.1200/JCO.2014.58.4391
   PubMed Web of Science ®Google Scholar
• Maria Kyrgiou AA, Arbyn M, Lax SF, et al. Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP. Lancet Oncol. 2022;23(8):385–392. doi:10.1016/S1470-2045(22)00191-7
   Web of Science ®Google Scholar
• Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Exploration. 2023;3:4. doi:10.1002/EXP.20210058
   Google Scholar
• Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2007;251(1):1–16. doi:10.1016/j.canlet.2006.10.007
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang S, Lin B, Wang Q, Nie X, Shi Y. Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. Front Oncol. 2022;12:974573. doi:10.3389/fonc.2022.974573
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang J, Cao J, Cao F, Chen X. Manipulating calcium homeostasis with nanoplatforms for enhanced cancer therapy. Exploration. 2023. doi:10.1002/EXP.20220173
   Google Scholar
• Pearcey R, B. M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20(4):966–972. doi:10.1200/JCO.2002.20.4.966
   PubMed Web of Science ®Google Scholar
• Sha Chen HB, Miao Y, Liu F, Zhang L. Clinical value of transvaginal color Doppler ultrasound in evaluating angiogenesis of cervical cancer. J Med Imaging. 2022;32(7):1254–1257.
   Google Scholar
• Shiliang Xu BB. Research of three-dimensional energy imaging detects cervical cancer and pathologic MVD. Chinese J Ultrasound Med. 2017;33(9):816–819.
   Google Scholar
• Tozer GM, K. C, Bruce C. Baguley disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423–435. doi:10.1038/nrc1628
   PubMed Web of Science ®Google Scholar
• Winn BA, Devkota L, Kuch B, et al. Bioreductively activatable prodrug conjugates of combretastatin A-1 and combretastatin A-4 as anticancer agents targeted toward tumor-associated hypoxia. J Nat Prod. 2020;83(4):937–954. doi:10.1021/acs.jnatprod.9b00773
   PubMed Web of Science ®Google Scholar
• Hong S, Huang Q-X, Ji P, et al. Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy. Sci China Chem. 2022;65(10):1994–2004. doi:10.1007/s11426-022-1347-9
   Web of Science ®Google Scholar
• Liu Z, Zhang Y, Shen N, Sun J, Tang Z, Chen X. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect. Adv Drug Deliv Rev. 2022;183:114138. doi:10.1016/j.addr.2022.114138
   PubMed Web of Science ®Google Scholar
• Lippert JW. Vascular disrupting agents. Bioorg Med Chem. 2007;15(2):605–615. doi:10.1016/j.bmc.2006.10.020
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Can Res. 2004;10(15):415–427. doi:10.1158/1078-0432.CCR-0642-03
   PubMedGoogle Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37(1):63–74. doi:10.1016/j.ctrv.2010.05.001
   PubMed Web of Science ®Google Scholar
• Wang K, Chen Q, Liu N, Zhang J, Pan X. Recent Advances in, and Challenges of, Anti-angiogenesis Agents for Tumor Chemotherapy Based on Vascular Normalization. Drug Discov Today. 2021;26(11):2743–2753. doi:10.1016/j.drudis.2021.07.024
   PubMed Web of Science ®Google Scholar
• Fruytier AC, Le Duff CS, Po C, et al. The blood flow shutdown induced by combretastatin A4 impairs gemcitabine delivery in a mouse hepatocarcinoma. Front Pharmacol. 2016;7:506. doi:10.3389/fphar.2016.00506
   PubMed Web of Science ®Google Scholar
• Li H, Zhou S, Wu M, et al. Light-driven self-recruitment of biomimetic semiconducting polymer nanoparticles for precise tumor vascular disruption. Adv Mater. 2023;35(24):e2210920. doi:10.1002/adma.202210920
   PubMed Web of Science ®Google Scholar
• Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, Samandari-Rad S, Zarghami N. An overview on Vadimezan (DMXAA): the vascular disrupting agent. Chem Biol Drug Des. 2018;91(5):996–1006. doi:10.1111/cbdd.13166
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu H, Zhang D, et al. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. Acta Biomater. 2019;92:229–240. doi:10.1016/j.actbio.2019.05.028
   PubMed Web of Science ®Google Scholar
• Tang Z, X C. Tumor-targeting drug delivery systems based on Poly(L-glutamic acid)-g-Poly(ethylene glycol). Acta Polymerica Sinica. 2019;50(6):543–552.
   Web of Science ®Google Scholar
• Li Z, Di C, Li S, Yang X, Nie G. Smart nanotherapeutic targeting of tumor vasculature. Acc Chem Res. 2019;52(9):2703–2712. doi:10.1021/acs.accounts.9b00283
   PubMed Web of Science ®Google Scholar
• Li B, Chu T, Wei J, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588–2595. doi:10.1021/acs.nanolett.1c00168
   PubMed Web of Science ®Google Scholar
• Liu Zhi-Lin RX-T, Yue H, Jia-Li S, et al. A Novel CA4P polymeric nanoparticle for murine hepatoma therapy. Chin J Poly Sci. 2023;41(8):1223–1229. doi:10.1007/s10118-023-2921-7
   Web of Science ®Google Scholar
• Zhilin Liu HZ, Sun J, Zheng M, et al. Organic-solvent-free “lego-like” modular preparation of fab-nondestructive antibody-drug conjugates with ultra-high drug-to-antibody ratio. Adv Mater. 2023. doi:10.1002/adma.202300377
   Web of Science ®Google Scholar
• Qin H, Yu H, Sheng J, et al. PI3Kgamma inhibitor attenuates immunosuppressive effect of poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in metastatic breast cancer. Adv Sci. 2019;6(12):1900327. doi:10.1002/advs.201900327
   Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666. doi:10.1016/j.biomaterials.2010.01.065
   PubMed Web of Science ®Google Scholar
• Kulkarni A, Chandrasekar V, Natarajan SK, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat Biomed Eng. 2018;2(8):589–599. doi:10.1038/s41551-018-0254-6
   PubMed Web of Science ®Google Scholar
• Strachan DC, R. B, Oei Y, Bissell MJ, Coussens LM, Pryer N. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. OncoImmunology. 2013;2(12):E26968. doi:10.4161/onci.26968
   PubMed Web of Science ®Google Scholar
• Rebelo SP, Pinto C, Martins TR, et al. 3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials. 2018;163:185–197. doi:10.1016/j.biomaterials.2018.02.030
   PubMed Web of Science ®Google Scholar
• Zhu D, Johnson TK, Wang Y, et al. Macrophage M2 polarization induced by exosomes from adipose-derived stem cells Contributes to the exosomal proangiogenic effect on mouse ischemic hindlimb. Stem Cell Res Ther. 2020;11(1):162. doi:10.1186/s13287-020-01669-9
   PubMed Web of Science ®Google Scholar
• Cui X, Ma C, Vasudevaraja V, et al. Dissecting the immunosuppressive tumor microenvironments in glioblastoma-on-a-chip for optimized PD-1 immunotherapy. Elife. 2020;9. doi:10.7554/eLife.52253
   Web of Science ®Google Scholar
• Huang Y, Yang C, Lv J, et al. Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy. Int J Pharm. 2023;636:122849. doi:10.1016/j.ijpharm.2023.122849
   PubMedGoogle Scholar
• Liu Z, Shen N, Tang Z, et al. An eximious and affordable GSH stimulus-responsive poly(alpha-lipoic acid) nanocarrier bonding combretastatin A4 for tumor therapy. Biomater Sci. 2019;7(7):2803–2811. doi:10.1039/C9BM00002J
   PubMed Web of Science ®Google Scholar
• Dan Peer JMK, Hong S, Farokhzad OC, Margalit R, Langer R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760. doi:10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951. doi:10.1038/nbt.3330
   PubMed Web of Science ®Google Scholar
• Xue X, Qu H, Li Y. Stimuli-responsive crosslinked nanomedicine for cancer treatment. Exploration. 2022;2(6):20210134. doi:10.1002/EXP.20210134
   Google Scholar
• De Jong W, Borm PJA. Drug delivery and nanoparticles applications and hazards. Int J Nanomedicine. 2008;3(2):133–149. doi:10.2147/IJN.S596
   PubMed Web of Science ®Google Scholar
• Yeh YC, Creran B, Rotello VM. Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale. 2012;4(6):1871–1880. doi:10.1039/C1NR11188D
   PubMed Web of Science ®Google Scholar
• Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759–1782. doi:10.1039/b806051g
   PubMed Web of Science ®Google Scholar
• Liu L, Li S, Yang K, et al. Drug-free antimicrobial nanomotor for precise treatment of multidrug-resistant bacterial infections. Nano Lett. 2023;23(9):3929–3938. doi:10.1021/acs.nanolett.3c00632
   PubMed Web of Science ®Google Scholar
• Luntao Liu YW, Jiamin Y, Qinrui F, et al. Synthesis of magnesium nanoparticle for NIR-II-photoacoustic-imaging-guided synergistic burst-like and H2 cancer therapy. Chem. 2022;8(11):2990–3007. doi:10.1016/j.chempr.2022.07.001
   Web of Science ®Google Scholar
• Liu L, Li Q, Chen L, et al. Plasmon enhanced catalysis-driven nanomotors with autonomous navigation for deep cancer imaging and enhanced radiotherapy. Chem Sci. 2022;13(43):12840–12850. doi:10.1039/D2SC03036E
   PubMed Web of Science ®Google Scholar
• Gu B, Feng H, Dong J, Zhang H, Bian X, Liu Y. The establishment and characterization of a continuous cell line of mouse cervical carcinoma. Chin J Clin Oncol. 2008;5(1):44–48. doi:10.1007/s11805-008-0044-0
   Google Scholar
• Feng CHEN, D. D, Yan FU, et al. Anti-tumor activity of biodegradable polymer-paclitaxel conjugated micelle against mice U14 cervical cancer. Chem Res Chin Universi. 2012;28(4):656–661.
   Web of Science ®Google Scholar
• Liu D, Duhamel J, Gauthier M. Synthesis and characterization of furan-based non-ionic surfactants (fbnios). Langmuir. 2023;39(26):8974–8983. doi:10.1021/acs.langmuir.3c00344
   PubMed Web of Science ®Google Scholar
• Negi SCK. Insight of molecular interactions between short-chain tetraalkylammonium bromides and cetyltrimethylammonium bromide: a spectroscopic and thermodynamic approach. J Hazard Mater. 2023;26(4):505–515.
   Google Scholar